Novavax Inc (NVAX)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$6.00

Buy

$6.02

arrow-down$-0.685 (-10.29%)

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Prices updated at 10 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Ms. Margaret G. McGlynn
CEO
Mr. John C. Jacobs
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,992
Head office
700 Quince Orchard Road
Gaithersburg
United States
20878
mobile
+1 240 268-2000
letter
ir@novavax.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Ms. Margaret G. McGlynn
Chairman of the Board
0.08m--0.47m-
Mr. Charles W. Newton
Independent Director
-----
Dr. John W. Shiver, PhD
Independent Director
-----
Dr. Gregg H. Alton, J.D.
Independent Director
0.07m--0.45m-
Mr. Richard J. Rodgers
Independent Director
0.09m--0.48m-
Mr. David M. Mott
Independent Director
0.08m--0.47m-
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer and Corporate Secretary
0.56m--1.06m-
Dr. Richard H. Douglas, PhD
Independent Director
0.08m--0.47m-
Mr. John J. Trizzino
President and Chief Operating Officer
0.58m--1.63m-
Ms. Rachel K. King
Independent Director
0.07m--0.46m-
Mr. John C. Jacobs
Director, President and Chief Executive Officer
0.75m--5.09m-
Mr. James P. Kelly
Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer
0.55m--1.83m-
Ms. Elaine O'Hara
Executive Vice President and Chief Strategy Officer
0.54m--1.64m-
Dr. Ruxandra Draghia-Akli
Executive Vice President and Head of Research and Development
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Vanguard Group Inc15,726,2500.00222961811.91950530 Apr 20259.71
Vanguard Group Inc. ( Junked)15,430,034-15430034-30 Apr 20259.63
BlackRock Inc13,450,4110.002199170757.31708630 Apr 20258.30
Shah Capital Management11,148,84618.07559133330513.58361230 Apr 20256.88
State Street Corp7,701,3660.00244134150.17449430 Apr 20254.75

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
31 Dec 2024-Dr. James F. Young, PhD8.0043,20051,760--
24 Dec 2024-Dr. James F. Young, PhD8.4839,00857,160--
13 Dec 2024-Ms. Rachel K. King9.0237,43514,770--
11 Dec 2024-Mr. Mark J. Casey8.82112,12929,187--
11 Dec 2024-Mr. Mark J. Casey--83,798--
11 Dec 2024-Mr. Mark J. Casey--41,900--
11 Nov 2024-Dr. Ruxandra Draghia-Akli--42,770--
11 Nov 2024-Dr. Ruxandra Draghia-Akli9.01577,99264,150--
29 Oct 2024-Mr. Richard J. Rodgers--14,270--
29 Oct 2024-Mr. Richard J. Rodgers--3,800--
19 Aug 2024-Mr. John J. Trizzino-----
19 Aug 2024-Mr. John J. Trizzino13.904,40628,310--
19 Aug 2024-Mr. John J. Trizzino--28,627--
21 Jun 2024-Dr. James F. Young, PhD14.09105,67561,760--
18 Jun 2024-Dr. James F. Young, PhD13.6287,07370,367--
18 Jun 2024-Dr. James F. Young, PhD14.2815,80869,260--
17 Jun 2024-Dr. Filip Dubovsky, M.D.6.0976,12580,517--
17 Jun 2024-Dr. Filip Dubovsky, M.D.6.0976,12537,500--
17 Jun 2024-Dr. Filip Dubovsky, M.D.6.979,78646,324--
17 Jun 2024-Dr. Filip Dubovsky, M.D.14.5420,41466,613--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.